ABSTRACT
Objective: To discuss the efficacy of Erzhu Erchentang on major cardiovascular risk factors caused by type 2 diabetes mellitus (T2DM)with phlegm turbidity and blood stasis syndrome, and its anti-inflammatory effect. Method: One hundred and forty-two patients were randomly divided into control group and observation group by random number table. Patients in control group got insulin or oral hypoglycemic drugs for controlling blood sugar, aspirin enteric-coated tablets, 100 mg/time, 1 time/day, telmisartan tablets, 40 mg/time, 1 time/day, atorvastatin, 10 mg/time, 1 time/day, and non-drug interventions. In addition to the therapy of control group, patients in observation group were also given modified Erzhu Erchentang, 1 dose/day, 5 times/week. The course of treatment was 24 weeks. And a 24-week follow-up was recorded. And levels of fasting blood glucose (FPG), 2 h postprandial blood glucose (2 hPG), glycosylated hemoglobin (HbA1c), systolic blood pressure (SBP), diastolic blood pressure (DBP), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HLD-C) and low-density lipoprotein (LDL-C) were detected. And the occurrence of major cardiovascular events, cerebrovascular events and peripheral vascular events were recorded. Before and after treatment, levels of body mass index (BMI), carotid intima-media thickness (IMT), framingham risk (FRS) and waist-hip ratio (WHR) were assessed. And procalcitonin (PCT), homocysteine (Hcy), hypersensitive C-reactive protein (hs-CRP), cystatin C (CysC) and matrix metalloproteinase-9 (MMP-9) were measured. Result: After treatment, levels of 2 hPG, HbA1c, SBP, DBP, TC, TG, LDL-C, IMT and BMI in observation group were lower than those in control group (PPχ2=4.775, Pχ2=5.639, PZ=2.165, PPConclusion: In addition to the comprehensive therapy of conventional western medicine, modified Erzhu Erchentang can increase the reduce serum inflammatory factors and control the high risk factors of cardiovascular disease of patients with T2DM, so as to reduce the major cardiovascular events.
ABSTRACT
Objective To investigate the molecular-epidemiologic characteristics and genotypes of human calicivirus (HuCVs) in acute diarrhea patients in Hangzhou from 2009 to 2010.Methods Epidemiologic data and fecal specimens were collected from patients with acute diarrhea.HuCVs of 920 specimens were detected by PCR.PCR products of several positive samples were randomly selected and sequenced.All the sequences were analyzed,phylogenetically.Results 201HuCVs positive cases were identified from 920 facal specimens (21.8％).25 isolates would include norovims G Ⅰ -type,G Ⅱ -type for 170 strains and sapovirus for 1 1 strains.Norovirus G Ⅰ -type and G Ⅱ -type were detected in four specimens at the same time.Other specimens were mixed infection with norovirus G Ⅱ -type and sapovirus.Genotypes of HuCVs showed that norovirus G Ⅰ subtypes were G Ⅰ -1 (3 strains) and G Ⅰ -2 (1 strain).Norovirus G Ⅱ subtypes were G Ⅱ -4/2006b variant strains (7 strains),GⅡ-2 (1 strain),G Ⅱ -7 (1 strain) and G Ⅱ -4/2008 variant strains (2 strains) ;Sapovirus subtypes were G Ⅰ -2 (5 strains),G Ⅰ -1 (4 strains) and G Ⅱ-1 ( 1 strain).The prevalence rates of HuCVs were different in seasons and age groups.Conclusion HuCVs were one of the major pathogens causing acute diarrhea.Both multiple viruses and genotypes of HuCVs were found in the specimens.G Ⅱ-4/2006b variant and similar strains were identified,probably as the prevalent strains from 2009 to 2010 in Hangzhou,Zhejiang province.
ABSTRACT
Chemokine receptor 5 (CCR5 ),as a member of the G protein-coupled receptor(GPCR)superfamily,is a membrane protein on cell surface and one of the major of coreceptors for HIV-1infection.CCR5 has became a molecular target for the novel drugs against HIV-1,and antagonists for CCR5 could be grouped as following, chemokine derivatives,small molecule non-peptide compounds,molecular antibodies and peptides. These compounds with high anti-viral activity and affinity are at different stages, and some have been under clinical studies. Therefore, the development research in the different kind of CCR5 antagonists is reviewed.